95 related articles for article (PubMed ID: 23584268)
1. CD133 is a selective marker of CRC?
Del Rio P; Bonati E; Crafa P; Campanini N; Montana Montana C; Bezer L; Dell'Abate P; Sianesi M
Minerva Chir; 2013 Feb; 68(1):87-95. PubMed ID: 23584268
[TBL] [Abstract][Full Text] [Related]
2. CD133 expression is correlated with poor prognosis in colorectal cancer.
Kashihara H; Shimada M; Kurita N; Iwata T; Sato H; Kozo Yoshikawa ; Higashijima J; Chikakiyo M; Nishi M; Matsumoto N
Hepatogastroenterology; 2014 Sep; 61(134):1563-7. PubMed ID: 25436343
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients.
Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A
Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425
[TBL] [Abstract][Full Text] [Related]
4. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.
Xi HQ; Zhao P
J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057
[TBL] [Abstract][Full Text] [Related]
6. AC133 expression associated with poor prognosis in stage II colorectal cancer.
Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W
Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518
[TBL] [Abstract][Full Text] [Related]
7. Patients with CD133-negative colorectal liver metastasis have a poor prognosis after hepatectomy.
Yamamoto S; Tanaka K; Takeda K; Akiyama H; Ichikawa Y; Nagashima Y; Endo I
Ann Surg Oncol; 2014 Jun; 21(6):1853-61. PubMed ID: 24554065
[TBL] [Abstract][Full Text] [Related]
8. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients.
Artells R; Moreno I; Díaz T; Martínez F; Gel B; Navarro A; Ibeas R; Moreno J; Monzó M
Eur J Cancer; 2010 Feb; 46(3):642-9. PubMed ID: 20005089
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of CD133 is associated with tumor regression grade after chemoradiotherapy in rectal cancer.
Hongo K; Kazama S; Sunami E; Tsuno NH; Takahashi K; Nagawa H; Kitayama J
Med Oncol; 2012 Dec; 29(4):2849-57. PubMed ID: 22246526
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.
Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY
J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373
[TBL] [Abstract][Full Text] [Related]
12. Circulating CD133(+)/ESA(+) cells in colorectal cancer patients.
Tseng JY; Yang CY; Yang SH; Lin JK; Lin CH; Jiang JK
J Surg Res; 2015 Dec; 199(2):362-70. PubMed ID: 26119272
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer.
Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M
J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.
Horst D; Kriegl L; Engel J; Kirchner T; Jung A
Cancer Invest; 2009 Oct; 27(8):844-50. PubMed ID: 19626493
[TBL] [Abstract][Full Text] [Related]
15. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of periostin in the liver metastasis of colorectal cancer.
Wu G; Wang X; Zhang X
Cancer Biother Radiopharm; 2013 May; 28(4):298-302. PubMed ID: 23347152
[TBL] [Abstract][Full Text] [Related]
17. CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.
Horst D; Kriegl L; Engel J; Jung A; Kirchner T
Eur J Cancer; 2009 Jul; 45(11):2034-40. PubMed ID: 19403300
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of CD133 expression in gastric carcinoma.
Ishigami S; Ueno S; Arigami T; Uchikado Y; Setoyama T; Arima H; Kita Y; Kurahara H; Okumura H; Matsumoto M; Kijima Y; Natsugoe S
Anticancer Res; 2010 Jun; 30(6):2453-7. PubMed ID: 20651407
[TBL] [Abstract][Full Text] [Related]
19. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients.
Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S
Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
Lönnroth C; Andersson M; Nordgren S; Lundholm K
Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]